Acurx Pharmaceuticals Inc ACXP

Healthcare Biotechnology

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

NDAQ:ACXP - Post by User

Acurx Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 23, 2024 9:45pm

91 Views

Post# 35896830

New to The Street Announces Line-up of its Corporate Intervi

JUST IN: $ACXP New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series | BenzingaNEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- FMW Media Work announces that its "New to The Street Leadership," Powered by Sector SPDR ETF...ACXP - New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series | Benzinga

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide